Promising Results of APHD-012 The phase 2 trials of APHD-012 have shown promising results, significantly improving glucose tolerance in prediabetes patients
Snag custom swag, get priority scheduling, and save on our most popular treatments
But now your skin is behaving like it belongs to someone else, reacting to bedsheets, clothing seams, even a gentle touch from another person
Formulators can incorporate GHK-Cu into recovery serums or creams to enhance healing and improve skin texture
In 2022, the company that owns the patent of Eriomin funded a small trial involving 45 people, concluding that those who took it over a 12-week period had lower blood glucose and higher GLP-1 than those who took a placebo
Transparent access to results Patients can review testing results for their compounded sterile GLP-1 medications through Boothwyn Pharmacys secure online portal here